01:47:15 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-12 Kvartalsrapport 2024-Q3
2024-08-13 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning MOB 0.00 SEK
2024-05-14 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-13 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-10-09 Extra Bolagsstämma 2023
2023-08-03 Kvartalsrapport 2023-Q2
2023-05-24 Split MOB 10:1
2023-05-17 Ordinarie utdelning MOB 0.00 SEK
2023-05-16 Årsstämma 2023
2023-05-09 Kvartalsrapport 2023-Q1
2023-02-07 Bokslutskommuniké 2022
2022-11-08 Kvartalsrapport 2022-Q3
2022-08-09 Kvartalsrapport 2022-Q2
2022-05-17 Ordinarie utdelning MOB 0.00 SEK
2022-05-16 Årsstämma 2022
2022-05-10 Kvartalsrapport 2022-Q1
2022-05-03 Extra Bolagsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-10 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-03-31 Ordinarie utdelning MOB 0.00 SEK
2021-03-30 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-01 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q3
2020-02-11 Kvartalsrapport 2020-Q2
2019-11-19 Kvartalsrapport 2020-Q1
2019-11-04 Inlösen MOB 46.5
2019-10-31 Ordinarie utdelning MOB 0.00 SEK
2019-10-30 Årsstämma 2020
2019-08-29 Bokslutskommuniké 2019
2019-05-16 Ordinarie utdelning MOB 0.00 SEK
2019-05-15 Årsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-03-15 Extra Bolagsstämma 2019
2019-02-12 Bokslutskommuniké 2018
2018-11-06 Kvartalsrapport 2018-Q3
2018-08-07 Kvartalsrapport 2018-Q2
2018-05-16 Ordinarie utdelning MOB 0.00 SEK
2018-05-15 Årsstämma 2018
2018-05-08 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-11-13 Kvartalsrapport 2017-Q3
2017-08-08 Kvartalsrapport 2017-Q2
2017-05-17 Ordinarie utdelning MOB 0.00 SEK
2017-05-16 Årsstämma 2017
2017-05-09 Kvartalsrapport 2017-Q1
2017-02-14 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-09 Kvartalsrapport 2016-Q2
2016-05-19 Ordinarie utdelning MOB 0.00 SEK
2016-05-18 Årsstämma 2016
2016-05-10 Kvartalsrapport 2016-Q1
2016-02-17 Bokslutskommuniké 2015
2015-11-10 Kvartalsrapport 2015-Q3
2015-08-11 Kvartalsrapport 2015-Q2
2015-05-12 Ordinarie utdelning MOB 0.00 SEK
2015-05-11 Årsstämma 2015
2015-05-11 Bokslutskommuniké 2014
2015-05-11 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-14 Ordinarie utdelning MOB 0.00 SEK
2014-05-13 Årsstämma 2014
2014-05-13 Kvartalsrapport 2014-Q1
2014-02-20 Bokslutskommuniké 2013
2013-11-05 Kvartalsrapport 2013-Q3
2013-08-06 Kvartalsrapport 2013-Q2
2013-05-21 Kvartalsrapport 2013-Q1
2013-05-21 Analytiker möte 2013
2013-04-24 Ordinarie utdelning MOB 0.00 SEK
2013-04-23 Årsstämma 2013
2013-03-13 15-7 2013
2013-02-05 Bokslutskommuniké 2012
2012-11-19 Extra Bolagsstämma 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-09-20 Kapitalmarknadsdag 2012
2012-08-28 Kvartalsrapport 2012-Q2
2012-06-11 15-7 2012
2012-04-24 Ordinarie utdelning MOB 0.00 SEK
2012-04-23 Årsstämma 2012
2012-04-23 Kvartalsrapport 2012-Q1
2012-02-09 Bokslutskommuniké 2011
2011-11-29 15-7 2011
2011-10-28 Kvartalsrapport 2011-Q3
2011-08-12 Kvartalsrapport 2011-Q2
2011-04-18 Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Moberg Pharma är ett svenskt läkemedelsbolag med fokus på kommersialisering av egenutvecklade läkemedel baserade på beprövade substanser. Bolaget arbetar framförallt inom nagelsvamp där Moberg Pharma utvecklar en ny utvärtes behandling. Moberg Pharma har avtal med kommersiella partners på plats i bland annat Europa och Kanada. Huvudkontoret ligger i Bromma.
2023-07-31 10:30:00

STOCKHOLM, July 31[st], 2023, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma's new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28[th] 2023.

The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to follow during upcoming months and timelines may vary between countries.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About this information
The information was submitted for publication, through the agency of the contact person set out above, on July 31[st], 2023, at 10.30 am CEST.

About MOB-015 and Onychomycosis 
Approximately 5-10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The global market opportunity is significant with more than hundred million patients worldwide and a clear demand for better products. Moberg Pharma estimates the annual worldwide peak sales potential for MOB-015 to be in the range of USD 250-500 million.

MOB-015 is an in-house developed topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. Oral terbinafine is currently the gold standard for treating onychomycosis but associated with safety issues, including drug interactions and liver damage. MOB-015 has recently been granted its first marketing authorization, and approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions.

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company's asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).